Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Pulmonology›Condition·Updated Jun 27, 2026·v1

Pulmonary Hypertension

Pulmonary hypertension is defined hemodynamically by mPAP >20 mmHg and comprises five WHO groups with distinct pathophysiologies. Diagnosis requires RHC with PAWP and PVR. Group 1 PAH is treated with upfront ERA+PDE5i combination, escalated to parenteral prostacyclin or sotatercept in high-risk patients. Group 4 CTEPH is potentially curable with PEA; inoperable cases use riociguat. The RV is the central determinant of outcomes; RV-PA uncoupling (Ees/Ea <0.8) identifies patients at highest risk. Key therapeutic advances include sotatercept (activin signaling inhibition) and the AMBITION regimen of ambrisentan + tadalafil.

High Evidence124 references·1,281 words·6 min read·v1
pulmonary hypertensionpulmonary arterial hypertensionright heart catheterizationprostacyclinsotaterceptCTEPHRV failure

Quick Reference

RxDrug of choiceEpoprostenol IV continuous infusion (2 ng/kg/min initial, titrate) for high-risk PAH; ambrisentan 10 mg + tadalafil 40 mg daily for low-risk (AMBITION regimen). For CTEPH: riociguat 2.5 mg TID.
AltAlternativesMacitentan 10 mg daily, sildenafil 20 mg TID, selexipag 200 mcg BID (oral), iloprost inhaled, sotatercept 0.3-0.7 mg/kg SC q3weeks
⊘AvoidPDE5 inhibitors with nitrates or riociguat; non-dihydropyridine CCBs (diltiazem, verapamil) in PAH; PAH-specific drugs in Group 2 or 3 PH (can worsen hemodynamics)
DxTest of choiceRight heart catheterization (RHC) to confirm mPAP >20 mmHg and classify pre- vs post-capillary (PAWP ≤15 vs >15 mmHg)
ScKey scoreWHO functional class (I-IV); 6-minute walk distance (<165 m high risk); NT-proBNP (<300, 300-1400, ≥1400 ng/L); REVEAL 2.0 risk score (incorporated in 2022 ESC/ERS guidelines)
→When to referAll new PH diagnoses should be referred to a PH center; urgent referral for WHO FC III/IV, syncope, acute RV failure, or CTEPH for PEA evaluation
PH requires RHC for diagnosis; treat based on WHO group, never use PAH drugs in Group 2. For Group 1, start upfront combination (ambrisentan + tadalafil); escalate to parenteral prostacyclin if high risk. CTEPH is potentially curable with PEA. The RV is the key prognostic organ, monitor coupling (Ees/Ea).
Pulmonary hypertension (PH) is a hemodynamic syndrome defined by mean pulmonary artery pressure >20 mmHg at rest. It encompasses five WHO groups with distinct etiologies. Accurate diagnosis via right heart catheterization is essential for management.

Overview and Recommendations

Background

  • •Pulmonary hypertension (PH) is a hemodynamic syndrome defined by a mean pulmonary artery pressure (mPAP) >20 mmHg, a threshold lowered in 2018 from >25 mmHg to reflect that normal mPAP is 14±3 mmHg and values 20-25 mmHg carry elevated risk. The syndrome affects ~1% of the global population, rising to >10% in those over age 65, driven largely by WHO Group 2 PH due to heart failure with preserved ejection fraction (HFpEF). PH is the third leading cause of cardiovascular death, with a 5-year survival of only 28% in WHO functional class IV despite modern therapy.
  • •The five WHO clinical groups capture divergent etiologies: Group 1 (pulmonary arterial hypertension, PAH) includes idiopathic, heritable (BMPR2 mutations in ~70%), drug-induced, connective tissue disease-associated, HIV, and portopulmonary hypertension; Group 2 (PH due to left heart disease) is the most common form; Group 3 (PH due to lung diseases/hypoxia) includes COPD and interstitial lung disease; Group 4 (chronic thromboembolic PH, CTEPH) is potentially curable with pulmonary endarterectomy; and Group 5 encompasses multifactorial mechanisms like sarcoidosis and metabolic disorders.
  • •The central pathophysiology in PAH (Group 1) is a cancer-like phenotype in pulmonary artery smooth muscle cells (PASMCs): they are proliferative, apoptosis-resistant, and metabolically reprogrammed toward glycolysis (Warburg effect) via suppressed Kv1.5 potassium channels and mitochondrial fragmentation. Endothelial dysfunction shifts the balance from vasodilation (NO/cGMP, prostacyclin) to vasoconstriction (endothelin-1). In IPAH, a landmark trial PATENT-1 (2013) showed riociguat improved 6-minute walk distance by +36 m; SERAPHIN (2013) demonstrated macitentan reduced morbidity/mortality (HR 0.55).
  • •Right ventricular (RV) adaptation determines clinical outcomes. The RV is afterload-sensitive; when mPAP exceeds ~40 mmHg, the RV transitions from compensatory hypertrophy to dilatation and failure (RV-PA uncoupling, Ees/Ea <0.8). The gold-standard measure of RV coupling is the Ees/Ea ratio, with a ratio <0.8 predicting clinical worsening and mortality. Speckle-tracking echocardiography provides a non-invasive surrogate via RV free-wall longitudinal strain (RV-FWS).

Evaluation

  • •Suspect PH in any patient with unexplained exertional dyspnea, fatigue, presyncope/syncope, or chest pain, especially if there is a history of connective tissue disease, HIV, portal hypertension, congenital heart disease, or a family history of PH.
  • •Ask about the timing and progression of dyspnea (insidious over months to years), orthopnea or paroxysmal nocturnal dyspnea (suggesting left heart disease, Group 2), prior pulmonary embolism or deep vein thrombosis (Group 4), sleep apnea or snoring (Group 3), and risk factors for HIV, drug/toxin use (anorexigens, methamphetamine), or Raynaud phenomenon (connective tissue disease).
  • •Examine for signs of right heart strain: elevated jugular venous pressure (JVP) with prominent a and v waves, a right ventricular heave at the left parasternal border, a loud P2 (pulmonary component of S2), and a holosystolic tricuspid regurgitation murmur that increases with inspiration. Also look for signs of RV failure: hepatomegaly, ascites, and peripheral edema.
  • •Examine for clues to underlying etiology: crackles suggest left heart disease (Group 2); digital clubbing or hyperresonance suggest lung disease (Group 3); telangiectasias or sclerodactyly suggest systemic sclerosis (Group 1). Perform a full cardiopulmonary exam including oxygen saturation at rest and with ambulation.
  • •Order transthoracic echocardiogram (TTE) as the first-line screening test. Estimate systolic pulmonary artery pressure (sPAP) from the tricuspid regurgitation jet velocity (4v² + right atrial pressure). High probability of PH is sPAP >45 mmHg or RV dilation/dysfunction. Normal TTE does not exclude PH, obtain RHC if clinical suspicion remains high.
  • •If TTE suggests PH, order right heart catheterization (RHC) for definitive diagnosis. RHC confirms mPAP >20 mmHg, measures pulmonary artery wedge pressure (PAWP) and cardiac output (by thermodilution or Fick), and calculates PVR = (mPAP - PAWP)/CO. Pre-capillary PH requires PAWP ≤15 mmHg and PVR >2 Wood units.
  • •During RHC, perform acute vasoreactivity testing with inhaled nitric oxide or epoprostenol in selected patients with IPAH (not in others). A positive response (mPAP drop >10 mmHg to ≤40 mmHg with preserved cardiac output) identifies candidates for high-dose calcium channel blocker therapy (~10% of IPAH patients).
  • •Use the diagnostic criteria from the 2022 ESC/ERS guidelines: the diagnosis of PH requires RHC with mPAP >20 mmHg. Group 1 (PAH) requires pre-capillary hemodynamics (PAWP ≤15, PVR >2 WU) and exclusion of other groups. Group 2 (PH-LHD) requires PAWP >15. Group 4 (CTEPH) requires mismatched perfusion defects on V/Q scan after ≥3 months of anticoagulation.
  • •Also consider: cardiac MRI for RV volumetric and functional assessment (gold standard for RVEF); pulmonary function tests with DLCO; high-resolution CT chest to exclude interstitial lung disease; V/Q scan to rule out CTEPH; and polysomnography if sleep apnea is suspected. Check NT-proBNP for baseline risk stratification (<300 ng/L low risk, ≥1400 ng/L high risk).
  • •Assess functional status using the WHO functional class (I-IV) and 6-minute walk distance. WHO FC II predicts better prognosis than III/IV. A 6-minute walk distance <165 m or desaturation to <88% during walk identifies high-risk patients.

Management

  • •Initiate therapy based on WHO group, never use PAH-specific therapies (endothelin receptor antagonists, PDE5 inhibitors, prostacyclin analogs) in Group 2 (PH-LHD) as they can worsen hemodynamics. For Group 4 CTEPH, refer for pulmonary endarterectomy (PEA) if anatomically suitable; inoperable CTEPH is treated with riociguat (2.5 mg TID, titrated from 1 mg TID).
  • •For Group 1 PAH, start combination therapy upfront in low- or intermediate-risk patients: ambrisentan 10 mg daily + tadalafil 40 mg daily (from AMBITION trial, 2015) reduced clinical failure by 50% vs monotherapy. For high-risk patients, initiate triple therapy including a parenteral prostacyclin.
  • •Administer endothelin receptor antagonists (ERAs): ambrisentan 5-10 mg daily; macitentan 10 mg daily (SERAPHIN trial, risk reduction HR 0.55); bosentan 62.5-125 mg BID, requires monthly LFT monitoring due to hepatotoxicity. ERAs are teratogenic, ensure negative pregnancy test monthly.
  • •Administer PDE5 inhibitors: sildenafil 20 mg TID (STARTS-1/2), but higher doses (40 mg TID) are associated with increased mortality; tadalafil 40 mg daily (PHIRST trial, +33 m 6MWD). Both are contraindicated with nitrates or riociguat due to risk of severe hypotension.
  • •Administer prostacyclin pathway agents: epoprostenol IV continuous infusion (start 2 ng/kg/min, titrate up by 1-2 ng/kg/min every 15 min as tolerated) is first-line for high-risk PAH; treprostinil SC/IV/inhaled; iloprost inhaled (2.5-5 mcg 6-9x daily). All cause infusion site pain, headache, flushing, jaw pain, and thrombocytopenia. Selexipag (oral IP receptor agonist, GRIPHON trial) reduces morbidity/mortality (HR 0.60).
  • •Administer riociguat (sGC stimulator) 1 mg TID, titrate to 2.5 mg TID as tolerated (PATENT-1, +36 m 6MWD, improved hemodynamics). Contraindicated with PDE5 inhibitors due to hypotension risk. Use only for PAH and CTEPH.
  • •For new approval: sotatercept (activin signaling inhibitor) 0.3-0.7 mg/kg SC every 3 weeks, targets vascular remodeling. In STELLAR trial (2023), it reduced clinical worsening (HR 0.52) and improved 6MWD (+33 m). Side effects include telangiectasia, GI bleeding, and thrombocytopenia. Reserved for advanced PAH in combination with other therapies.
  • •Titrate to target doses: ambrisentan 10 mg daily, macitentan 10 mg daily, sildenafil 20 mg TID, tadalafil 40 mg daily. For epoprostenol, target dose is typically 30-50 ng/kg/min. Escalate therapy if WHO FC deteriorates or 6-minute walk distance declines >10%. Reassess risk at 3-6 months: if intermediate or high risk, escalate to triple therapy.
  • •Monitor with echocardiogram every 6-12 months and every 3 months in high-risk patients. NT-proBNP every 3 months; 6-minute walk test at each visit. Check LFTs monthly before ERAs. For CTEPH post-PEA, repeat RHC at 3-6 months to assess residual PH.
  • •What NOT to do: avoid non-dihydropyridine CCBs (diltiazem, verapamil) in PAH, they reduce contractility and can worsen RV function. Do not use PAH-specific therapies in Group 2 or 3 PH. Do not use high-dose sildenafil (40 mg TID) due to mortality signal.
  • •Refer to a pulmonary hypertension center for all newly diagnosed PH, especially for RHC interpretation, vasoreactivity testing, and consideration of lung transplantation. Refer for PEA if CTEPH is anatomically suitable. Refer for lung or heart-lung transplantation if WHO FC III/IV despite maximal therapy.
  • •For acute decompensated RV failure: admit to ICU, reduce RV afterload with parenteral prostacyclin (epoprostenol), consider inotropes (dobutamine 2-20 mcg/kg/min, milrinone 0.125-0.75 mcg/kg/min), diurese for volume overload (furosemide IV 40-80 mg, titrate to urine output), and avoid positive pressure ventilation if possible (reduces preload). Discharge criteria include stable hemodynamics, improving RV function, and ability to tolerate oral therapy.

Board Review — High Yield

  • •mPAP >20 mmHg, new 2018 threshold; down from >25 mmHg, based on normal 14±3 mmHg
  • •RHC is mandatory, echocardiogram estimates probability but cannot confirm PH or group
  • •WHO Group 2, most common PH; due to left heart disease (HFpEF, valvular); PAWP >15 mmHg
  • •Estrogen paradox, women have 3-4× higher PAH incidence but better RV function and survival
  • •BMPR2 mutation, found in ~70% of heritable PAH; causes PASMC proliferation and apoptosis resistance
  • •Sotatercept, activin signaling inhibitor; reduces clinical worsening (HR 0.52) and improves 6MWD (+33 m)
  • •CTEPH, occurs in 3-5% after acute PE; treat with PEA; inoperable cases use riociguat
  • •Kv1.5 suppression, depolarizes PASMC, inhibits apoptosis, promotes contraction, key in PAH
  • •Ees/Ea <0.8, RV-PA uncoupling; predicts clinical worsening and mortality
  • •10% radius reduction → 46% PVR increase, fourth-power relationship; explains severity of early remodeling

Deep Dive — Evidence Details

References

  1. [1]

    Dempsey JA, Veasey SC, Morgan BJ et al.. “Pathophysiology of sleep apnea.” Physiological reviews (2010). PMID: 20086074 ↗

    L5REVIEW_NARRATIVECited in: Definition & Physiological Scope, Regulation & Feedback Control, Integration with Other Systems, Clinical Correlation: From Derangement to Disease, Key Pearls, Common Misconceptions & Self-Test
  2. [2]

    Suresh K, Shimoda LA. “Lung Circulation.” Comprehensive Physiology (2016). PMID: 27065170 ↗

    L5REVIEW_NARRATIVECited in: Definition & Physiological Scope, Integration with Other Systems
  3. [3]

    Bravo-Sagua R, Parra V, López-Crisosto C et al.. “Calcium Transport and Signaling in Mitochondria.” Comprehensive Physiology (2017). PMID: 28333383 ↗

    L5REVIEW_NARRATIVECited in: Definition & Physiological Scope, Regulation & Feedback Control, Clinical Correlation: From Derangement to Disease, Key Pearls, Common Misconceptions & Self-Test
  4. [4]

    Schmidt EP, Kuebler WM, Lee WL et al.. “Adhesion Molecules: Master Controllers of the Circulatory System.” Comprehensive Physiology (2016). PMID: 27065171 ↗

    L5REVIEW_NARRATIVECited in: Definition & Physiological Scope, Clinical Correlation: From Derangement to Disease
  5. [5]

    Prabala P, Raza F, Chesler NC. “Heart-Lung Interactions in Pulmonary Hypertension due to Heart Failure With Preserved Ejection Fraction.” Comprehensive Physiology (2026). PMID: 42138604 ↗

    L5REVIEW_NARRATIVECited in: Definition & Physiological Scope, Integration with Other Systems, Quantitative Parameters, Equations & Curves, Physiological Variation
  6. [6]

    Shi J, Yang Y, Cheng A et al.. “Metabolism of vascular smooth muscle cells in vascular diseases.” American journal of physiology. Heart and circulatory physiology (2020). PMID: 32762559 ↗

    L5REVIEW_NARRATIVECited in: Definition & Physiological Scope, Integration with Other Systems, Physiological Variation, Clinical Correlation: From Derangement to Disease, Key Pearls, Common Misconceptions & Self-Test
  7. [7]

    Poels EM, da Costa Martins PA, van Empel VP. “Adaptive capacity of the right ventricle: why does it fail?” American journal of physiology. Heart and circulatory physiology (2015). PMID: 25681425 ↗

    L5REVIEW_NARRATIVECited in: Definition & Physiological Scope, Normal Process & Mechanism (First Principles), Physiological Variation
  8. [8]

    Lennon FE, Singleton PA. “Role of hyaluronan and hyaluronan-binding proteins in lung pathobiology.” American journal of physiology. Lung cellular and molecular physiology (2011). PMID: 21571904 ↗

    L5REVIEW_NARRATIVECited in: Definition & Physiological Scope, Regulation & Feedback Control
  9. [9]

    Lin Q, Johns RA. “Resistin family proteins in pulmonary diseases.” American journal of physiology. Lung cellular and molecular physiology (2020). PMID: 32692581 ↗

    L5REVIEW_NARRATIVECited in: Definition & Physiological Scope, Clinical Correlation: From Derangement to Disease
  10. [10]

    Mora Massad K, Dai Z, Petrache I et al.. “Lung endothelial cell heterogeneity in health and pulmonary vascular disease.” American journal of physiology. Lung cellular and molecular physiology (2025). PMID: 39772753 ↗

    L5REVIEW_NARRATIVECited in: Definition & Physiological Scope, Clinical Correlation: From Derangement to Disease, Key Pearls, Common Misconceptions & Self-Test
  11. [11]

    Marshall JD, Bazan I, Zhang Y et al.. “Mitochondrial dysfunction and pulmonary hypertension: cause, effect, or both.” American journal of physiology. Lung cellular and molecular physiology (2018). PMID: 29345195 ↗

    L5REVIEW_NARRATIVECited in: Definition & Physiological Scope, Integration with Other Systems, Clinical Correlation: From Derangement to Disease, Key Pearls, Common Misconceptions & Self-Test
  12. [12]

    Lasa JJ, Dhillon GS, Duff JP et al.. “Part 8: Pediatric Advanced Life Support: 2025 American Heart Association and American Academy of Pediatrics Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care.” Circulation (2025). PMID: 41122885 ↗

    L1GUIDELINECited in: Definition & Physiological Scope
  13. [13]

    Lasa JJ, Dhillon GS, Duff JP et al.. “Part 8: Pediatric Advanced Life Support: 2025 American Heart Association and American Academy of Pediatrics Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care.” Pediatrics (2026). PMID: 41122862 ↗

    L1GUIDELINECited in: Definition & Physiological Scope
  14. [14]

    Marozkina NV, Gaston B. “Nitrogen chemistry and lung physiology.” Annual review of physiology (2015). PMID: 25668023 ↗

    L5REVIEW_NARRATIVECited in: Definition & Physiological Scope, Clinical Correlation: From Derangement to Disease, Key Pearls, Common Misconceptions & Self-Test
  15. [15]

    Chaurembo AI, Xing N, Huang ZF et al.. “Echoes in the powerhouse: mito-lncRNAs contribution to cardiac function and disease.” Acta pharmacologica Sinica (2026). PMID: 42236984 ↗

    L5REVIEW_NARRATIVECited in: Definition & Physiological Scope, Regulation & Feedback Control
  16. [16]

    Hari Gopal S, Parmekar S, Dempsey E et al.. “Caring for the smallest hearts: cardiovascular phenotypes and assessment in tiny babies.” Pediatric research (2026). PMID: 42236923 ↗

    L5REVIEW_NARRATIVECited in: Definition & Physiological Scope
  17. [17]

    Saint-Martin Willer A, Santos-Gomes J, Adão R et al.. “Physiological and pathophysiological roles of the KCNK3 potassium channel in the pulmonary circulation and the heart.” The Journal of physiology (2023). PMID: 37477289 ↗

    L5REVIEW_NARRATIVECited in: Definition & Physiological Scope, Clinical Correlation: From Derangement to Disease
  18. [18]

    Feliciangeli S, Chatelain FC, Bichet D et al.. “The family of K2P channels: salient structural and functional properties.” The Journal of physiology (2015). PMID: 25530075 ↗

    L5REVIEW_NARRATIVECited in: Definition & Physiological Scope
  19. [19]

    Duke JW, Lewandowski AJ, Abman SH et al.. “Physiological aspects of cardiopulmonary dysanapsis on exercise in adults born preterm.” The Journal of physiology (2022). PMID: 34961925 ↗

    L5REVIEW_NARRATIVECited in: Definition & Physiological Scope, Physiological Variation, Clinical Correlation: From Derangement to Disease
  20. [20]

    Schibalski RS, Shulha AS, Tsao BP et al.. “The role of polyamine metabolism in cellular function and physiology.” American journal of physiology. Cell physiology (2024). PMID: 38881422 ↗

    L5REVIEW_NARRATIVECited in: Definition & Physiological Scope, Regulation & Feedback Control, Physiological Variation, Clinical Correlation: From Derangement to Disease
  21. [21]

    Hagood JS. “Beyond the genome: epigenetic mechanisms in lung remodeling.” Physiology (Bethesda, Md.) (2014). PMID: 24789982 ↗

    L5REVIEW_NARRATIVECited in: Definition & Physiological Scope, Regulation & Feedback Control, Physiological Variation, Clinical Correlation: From Derangement to Disease
  22. [22]

    Sonveaux P, Lobysheva II, Feron O et al.. “Transport and peripheral bioactivities of nitrogen oxides carried by red blood cell hemoglobin: role in oxygen delivery.” Physiology (Bethesda, Md.) (2007). PMID: 17420301 ↗

    L5REVIEW_NARRATIVECited in: Definition & Physiological Scope, Regulation & Feedback Control, Integration with Other Systems
  23. [23]

    West J, Hemnes A. “Experimental and transgenic models of pulmonary hypertension.” Comprehensive Physiology (2011). PMID: 23737202 ↗

    L5REVIEW_NARRATIVECited in: Normal Process & Mechanism (First Principles), Integration with Other Systems, Quantitative Parameters, Equations & Curves, Clinical Correlation: From Derangement to Disease
  24. [24]

    Zhang H, Prasad RR, Kumar S et al.. “Adventitial Niches, Complement and Inflammation in Pulmonary Vascular Disease: Current Status and Future Directions.” Comprehensive Physiology (2026). PMID: 41889113 ↗

    L5REVIEW_NARRATIVECited in: Normal Process & Mechanism (First Principles)
  25. [25]

    Satoh K, Fukumoto Y, Shimokawa H. “Rho-kinase: important new therapeutic target in cardiovascular diseases.” American journal of physiology. Heart and circulatory physiology (2011). PMID: 21622831 ↗

    L5REVIEW_NARRATIVECited in: Normal Process & Mechanism (First Principles)
  26. [26]

    Archer SL, Gomberg-Maitland M, Maitland ML et al.. “Mitochondrial metabolism, redox signaling, and fusion: a mitochondria-ROS-HIF-1alpha-Kv1.5 O2-sensing pathway at the intersection of pulmonary hypertension and cancer.” American journal of physiology. Heart and circulatory physiology (2007). PMID: 18083891 ↗

    L5REVIEW_NARRATIVECited in: Normal Process & Mechanism (First Principles)
  27. [27]

    Penumatsa KC, Fanburg BL. “Transglutaminase 2-mediated serotonylation in pulmonary hypertension.” American journal of physiology. Lung cellular and molecular physiology (2013). PMID: 24375797 ↗

    L5REVIEW_NARRATIVECited in: Normal Process & Mechanism (First Principles), Clinical Correlation: From Derangement to Disease
  28. [28]

    Liu H, Song T, Huang Y. “The mechanism of m6A modification in cardiovascular diseases: A systematic review.” Genes & diseases (2025). PMID: 41112525 ↗

    L5SR_OBSCited in: Normal Process & Mechanism (First Principles)
  29. [29]

    Alqarni AA, Alghamdi SA, Aldhahir AM et al.. “Drugs targeting the NO-sGC-cGMP pathway in the treatment of patients with COPD-associated pulmonary hypertension: a systematic review.” Frontiers in pharmacology (2025). PMID: 40978475 ↗

    L1SR_OBSCited in: Normal Process & Mechanism (First Principles)
  30. [30]

    Epelde F. “Heterogeneity in Heart Failure with Preserved Ejection Fraction: A Systematic Review of Phenotypic Classifications and Clinical Implications.” Journal of clinical medicine (2025). PMID: 40725513 ↗

    L5SR_OBSCited in: Normal Process & Mechanism (First Principles)
  31. [31]

    Amirsardari Z, Khalili A, Sharafi M et al.. “Metabolomics profiling in venous thromboembolism and its chronic sequelae - A systematic review.” Thrombosis research (2025). PMID: 40121920 ↗

    L1SR_OBSCited in: Normal Process & Mechanism (First Principles)
  32. [32]

    Pang L, Du S, Wu S et al.. “Genetic assessment of the causal relationship between obstructive sleep apnea and pulmonary hypertension: Mendelian randomization and meta-analysis.” Respiratory medicine (2026). PMID: 41812932 ↗

    L2SR_OBSCited in: Normal Process & Mechanism (First Principles)
  33. [33]

    Zhang J, Chen J, Li SG et al.. “Case Report: A multidisciplinary, protocol-driven pathway from recurrent pregnancy loss to live birth in an anti-Ro/SSA-positive primary Sjögren's syndrome pregnancy with literature review.” Frontiers in immunology (2026). PMID: 41624857 ↗

    L4CASE_REPORTCited in: Normal Process & Mechanism (First Principles)
  34. [34]

    Huang AP, Voskamp S, Ebadi AA et al.. “Meta-analysis of differential gene expression in idiopathic pulmonary arterial hypertension.” Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology (2025). PMID: 41352442 ↗

    L1SR_OBSCited in: Normal Process & Mechanism (First Principles)
  35. [35]

    Smith KA, Schumacker PT. “Sensors and signals: the role of reactive oxygen species in hypoxic pulmonary vasoconstriction.” The Journal of physiology (2018). PMID: 30091476 ↗

    L5REVIEW_NARRATIVECited in: Normal Process & Mechanism (First Principles)
  36. [36]

    Slingo ME. “Oxygen-sensing pathways and the pulmonary circulation.” The Journal of physiology (2023). PMID: 37843154 ↗

    L5REVIEW_NARRATIVECited in: Normal Process & Mechanism (First Principles), Physiological Variation, Clinical Correlation: From Derangement to Disease, Key Pearls, Common Misconceptions & Self-Test
  37. [37]

    Hu CJ, Zhang H, Laux A et al.. “Mechanisms contributing to persistently activated cell phenotypes in pulmonary hypertension.” The Journal of physiology (2018). PMID: 29920674 ↗

    L5REVIEW_NARRATIVECited in: Normal Process & Mechanism (First Principles), Clinical Correlation: From Derangement to Disease
  38. [38]

    Pearce WJ. “Mitochondrial influences on smooth muscle phenotype.” American journal of physiology. Cell physiology (2023). PMID: 38009196 ↗

    L5REVIEW_NARRATIVECited in: Normal Process & Mechanism (First Principles), Regulation & Feedback Control
  39. [39]

    Qin HL, Bao JH, Tang JJ et al.. “Arterial remodeling: the role of mitochondrial metabolism in vascular smooth muscle cells.” American journal of physiology. Cell physiology (2022). PMID: 36468843 ↗

    L5REVIEW_NARRATIVECited in: Normal Process & Mechanism (First Principles), Quantitative Parameters, Equations & Curves, Clinical Correlation: From Derangement to Disease, Key Pearls, Common Misconceptions & Self-Test
  40. [40]

    Douma LG, Barral D, Gumz ML. “Interplay of the Circadian Clock and Endothelin System.” Physiology (Bethesda, Md.) (2021). PMID: 33325818 ↗

    L5REVIEW_NARRATIVECited in: Normal Process & Mechanism (First Principles), Regulation & Feedback Control, Clinical Correlation: From Derangement to Disease, Key Pearls, Common Misconceptions & Self-Test
  41. [41]

    Balistrieri A, Makino A, Yuan JX. “Pathophysiology and pathogenic mechanisms of pulmonary hypertension: role of membrane receptors, ion channels, and Ca2+ signaling.” Physiological reviews (2022). PMID: 36422993 ↗

    L5REVIEW_NARRATIVECited in: Regulation & Feedback Control, Quantitative Parameters, Equations & Curves, Clinical Correlation: From Derangement to Disease, Key Pearls, Common Misconceptions & Self-Test
  42. [42]

    Garrud TAC, Collier DM, Jaggar JH. “Potassium channels in vascular smooth muscle cells.” Physiological reviews (2026). PMID: 41526008 ↗

    L5REVIEW_NARRATIVECited in: Regulation & Feedback Control, Integration with Other Systems, Physiological Variation
  43. [43]

    Gao Y, Raj JU. “Regulation of the pulmonary circulation in the fetus and newborn.” Physiological reviews (2010). PMID: 20959617 ↗

    L5REVIEW_NARRATIVECited in: Regulation & Feedback Control
  44. [44]

    Makino A, Firth AL, Yuan JX. “Endothelial and smooth muscle cell ion channels in pulmonary vasoconstriction and vascular remodeling.” Comprehensive Physiology (2011). PMID: 23733654 ↗

    L5REVIEW_NARRATIVECited in: Regulation & Feedback Control, Quantitative Parameters, Equations & Curves, Clinical Correlation: From Derangement to Disease
  45. [45]

    Davis PJ, Sudha T, Lin HY et al.. “Thyroid Hormone, Hormone Analogs, and Angiogenesis.” Comprehensive Physiology (2015). PMID: 26756636 ↗

    L5REVIEW_NARRATIVECited in: Regulation & Feedback Control
  46. [46]

    Xu W, Erzurum SC. “Endothelial cell energy metabolism, proliferation, and apoptosis in pulmonary hypertension.” Comprehensive Physiology (2011). PMID: 23737177 ↗

    L5REVIEW_NARRATIVECited in: Regulation & Feedback Control, Clinical Correlation: From Derangement to Disease, Key Pearls, Common Misconceptions & Self-Test
  47. [47]

    Gilfillan M, Bhandari V. “Moving bronchopulmonary dysplasia research from the bedside to the bench.” American journal of physiology. Lung cellular and molecular physiology (2022). PMID: 35437999 ↗

    L5REVIEW_NARRATIVECited in: Regulation & Feedback Control
  48. [48]

    Chen Q, Ren C, Shu C et al.. “Hypertension-gut microbiota research trends: a bibliometric and visualization analysis (2000-2025).” Frontiers in microbiology (2025). PMID: 40873701 ↗

    L2SR_OBSCited in: Regulation & Feedback Control
  49. [49]

    Freire TC, Ferreira MS, De Angelis K et al.. “Respiratory, cardiovascular and musculoskeletal mechanisms involved in the pathophysiology of pulmonary hypertension: An updated systematic review of preclinical and clinical studies.” Heart & lung : the journal of critical care (2024). PMID: 38941771 ↗

    L1SR_OBSCited in: Regulation & Feedback Control
  50. [50]

    Xu W, Janocha AJ, Erzurum SC. “Metabolism in Pulmonary Hypertension.” Annual review of physiology (2021). PMID: 33566674 ↗

    L5REVIEW_NARRATIVECited in: Regulation & Feedback Control, Clinical Correlation: From Derangement to Disease, Key Pearls, Common Misconceptions & Self-Test
  51. [51]

    Song J, Zhang X, Mu H et al.. “Research progress on high-altitude hypoxia pulmonary injury: pathogenesis and Chinese herbal medicine for prevention and treatment.” Frontiers in pharmacology (2026). PMID: 42131810 ↗

    L5REVIEW_NARRATIVECited in: Regulation & Feedback Control
  52. [52]

    Leong XF. “Pterostilbene in Cardiovascular Diseases: From Molecular Mechanisms to Therapeutic Potential.” Biomedicines (2026). PMID: 42072399 ↗

    L5REVIEW_NARRATIVECited in: Regulation & Feedback Control
  53. [53]

    Zhu Y, Yang X, Cao X et al.. “From nanotechnology to immunomodulation: emerging strategies targeting macrophages in high altitude pulmonary hypertension.” Journal of nanobiotechnology (2026). PMID: 41933337 ↗

    L5REVIEW_NARRATIVECited in: Regulation & Feedback Control
  54. [54]

    Wang WT, Li X, Wang T et al.. “Pulmonary Vascular Signaling in Pulmonary Hypertension: Potential Role of Endothelial Ca2+ Signaling in Cellular Senescence and Inflammasome Activation.” Arteriosclerosis, thrombosis, and vascular biology (2026). PMID: 41815086 ↗

    L5REVIEW_NARRATIVECited in: Regulation & Feedback Control
  55. [55]

    Veith C, Schermuly RT, Brandes RP et al.. “Molecular mechanisms of hypoxia-inducible factor-induced pulmonary arterial smooth muscle cell alterations in pulmonary hypertension.” The Journal of physiology (2015). PMID: 26228924 ↗

    L5REVIEW_NARRATIVECited in: Regulation & Feedback Control, Quantitative Parameters, Equations & Curves, Clinical Correlation: From Derangement to Disease, Key Pearls, Common Misconceptions & Self-Test
  56. [56]

    Harvey LD, Chan SY. “Evolving systems biology approaches to understanding non-coding RNAs in pulmonary hypertension.” The Journal of physiology (2018). PMID: 30113078 ↗

    L5REVIEW_NARRATIVECited in: Regulation & Feedback Control
  57. [57]

    Luo JY, Zhang Y, Wang L et al.. “Regulators and effectors of bone morphogenetic protein signalling in the cardiovascular system.” The Journal of physiology (2015). PMID: 25952563 ↗

    L5REVIEW_NARRATIVECited in: Regulation & Feedback Control
  58. [58]

    MacKay CE, Knock GA. “Control of vascular smooth muscle function by Src-family kinases and reactive oxygen species in health and disease.” The Journal of physiology (2014). PMID: 25384773 ↗

    L5REVIEW_NARRATIVECited in: Regulation & Feedback Control
  59. [59]

    Wolter NL, Jaffe IZ. “Emerging vascular cell-specific roles for mineralocorticoid receptor: implications for understanding sex differences in cardiovascular disease.” American journal of physiology. Cell physiology (2022). PMID: 36440858 ↗

    L5REVIEW_NARRATIVECited in: Regulation & Feedback Control, Clinical Correlation: From Derangement to Disease, Key Pearls, Common Misconceptions & Self-Test
  60. [60]

    Fuenderich MT, Yogeswaran A, Janetzko P et al.. “PVRI-GoDeep-A Global Meta-Registry at the Crossroads of Heart and Lung.” Comprehensive Physiology (2026). PMID: 41876955 ↗

    L2REVIEW_NARRATIVECited in: Integration with Other Systems
  61. [61]

    Sehgal A, South AM, Menahem S. “Systemic hemodynamics and pediatric lung disease: mechanistic links and therapeutic relevance.” American journal of physiology. Heart and circulatory physiology (2024). PMID: 38968163 ↗

    L5REVIEW_NARRATIVECited in: Integration with Other Systems, Clinical Correlation: From Derangement to Disease
  62. [62]

    Rodrigues PG, Leite-Moreira AF, Falcão-Pires I. “Myocardial reverse remodeling: how far can we rewind?” American journal of physiology. Heart and circulatory physiology (2016). PMID: 26993225 ↗

    L5REVIEW_NARRATIVECited in: Integration with Other Systems, Clinical Correlation: From Derangement to Disease
  63. [63]

    Agrawal A, Mabalirajan U. “Rejuvenating cellular respiration for optimizing respiratory function: targeting mitochondria.” American journal of physiology. Lung cellular and molecular physiology (2015). PMID: 26566906 ↗

    L5REVIEW_NARRATIVECited in: Integration with Other Systems
  64. [64]

    Pugliese SC, Poth JM, Fini MA et al.. “The role of inflammation in hypoxic pulmonary hypertension: from cellular mechanisms to clinical phenotypes.” American journal of physiology. Lung cellular and molecular physiology (2014). PMID: 25416383 ↗

    L5REVIEW_NARRATIVECited in: Integration with Other Systems
  65. [65]

    Cealera E, Gurzun MM, Gache AC et al.. “Right Ventricular Strain and RV-Pulmonary Artery Coupling in Systemic Sclerosis: A Systematic Review.” Journal of clinical medicine (2026). PMID: 42123103 ↗

    L2SR_OBSCited in: Integration with Other Systems, Quantitative Parameters, Equations & Curves, Measurement & Assessment Methods, Key Pearls, Common Misconceptions & Self-Test
  66. [66]

    Sonaglioni A, Baravelli M, Gramaglia GF et al.. “Unmasking Risk in Mitral Regurgitation: Prognostic Value of Exercise Stress Echocardiography-A Systematic Review.” Journal of clinical medicine (2026). PMID: 42122985 ↗

    L2SR_OBSCited in: Integration with Other Systems, Measurement & Assessment Methods, Physiological Variation, Key Pearls, Common Misconceptions & Self-Test
  67. [67]

    Sonaglioni A, Lombardo M, Gramaglia GF et al.. “The Prognostic Value of Exercise Stress Echocardiography in Asymptomatic Moderate and Severe Aortic Stenosis: A Systematic Review of Stress-Derived Hemodynamic and Functional Markers.” Journal of clinical medicine (2026). PMID: 42122979 ↗

    L2SR_OBSCited in: Integration with Other Systems, Measurement & Assessment Methods, Physiological Variation
  68. [68]

    Long T, Li J, Li SG et al.. “SLE-associated intestinal pseudo-obstruction: a case report and analysis of 43 cases.” Frontiers in immunology (2026). PMID: 42088489 ↗

    L4SR_OBSCited in: Integration with Other Systems
  69. [69]

    Georgakopoulou VE, Steiropoulos P, Androutsakos T et al.. “Metabolic Dysfunction-Associated Steatotic Liver Disease and Respiratory Disorders: A Systematic Review of Clinical and Pathophysiological Associations.” Current obesity reports (2026). PMID: 41995935 ↗

    L2SR_OBSCited in: Integration with Other Systems
  70. [70]

    Luo Z, Li J, Liu X et al.. “Prediction Models for Severe Maternal Outcomes in Non-ICU Settings: Systematic Review.” BJOG : an international journal of obstetrics and gynaecology (2026). PMID: 41487074 ↗

    L2SR_OBSCited in: Integration with Other Systems, Physiological Variation
  71. [71]

    Dromparis P, Michelakis ED. “Mitochondria in vascular health and disease.” Annual review of physiology (2012). PMID: 23157555 ↗

    L5REVIEW_NARRATIVECited in: Integration with Other Systems, Clinical Correlation: From Derangement to Disease, Key Pearls, Common Misconceptions & Self-Test
  72. [72]

    Chan SY, Loscalzo J. “Pulmonary vascular disease related to hemodynamic stress in the pulmonary circulation.” Comprehensive Physiology (2011). PMID: 23737167 ↗

    L5REVIEW_NARRATIVECited in: Quantitative Parameters, Equations & Curves
  73. [73]

    Auger WR, Krasuski RA, Mahmud E et al.. “Balloon Pulmonary Angioplasty for Treatment of Chronic Thromboembolic Pulmonary Hypertension: Statement From the BPA-CTEPH Alliance.” JACC. Cardiovascular interventions (2026). PMID: 42055655 ↗

    L1GUIDELINECited in: Quantitative Parameters, Equations & Curves
  74. [74]

    Thenappan T, Chan SY, Weir EK. “Role of extracellular matrix in the pathogenesis of pulmonary arterial hypertension.” American journal of physiology. Heart and circulatory physiology (2018). PMID: 30141981 ↗

    L5REVIEW_NARRATIVECited in: Quantitative Parameters, Equations & Curves, Clinical Correlation: From Derangement to Disease
  75. [75]

    Price LC, McAuley DF, Marino PS et al.. “Pathophysiology of pulmonary hypertension in acute lung injury.” American journal of physiology. Lung cellular and molecular physiology (2012). PMID: 22246001 ↗

    L5REVIEW_NARRATIVECited in: Quantitative Parameters, Equations & Curves
  76. [76]

    Hundscheid TM, Amodeo I, Cavallaro G et al.. “Antenatal Sildenafil for Congenital Diaphragmatic Hernia: A Systematic Review and Bayesian Meta-Analysis of Preclinical Studies.” Biomedicines (2025). PMID: 41007834 ↗

    L1SR_OBSCited in: Quantitative Parameters, Equations & Curves
  77. [77]

    Richardson NT, Jahnel RE, Makanjuola BO et al.. “Meta-analysis of poultry organ weights and their relationship with meat yield.” Poultry science (2025). PMID: 40912146 ↗

    L5SR_OBSCited in: Quantitative Parameters, Equations & Curves
  78. [78]

    Alghamdi KS, Maiter A, Hyde GA et al.. “Pulmonary hypertension and the role of MRI flow assessment: a systematic review.” The British journal of radiology (2025). PMID: 40711861 ↗

    L2SR_OBSCited in: Quantitative Parameters, Equations & Curves
  79. [79]

    Kramer M, Rosenkranz S, Kramer T. “Depression in Pulmonary Hypertension: A Systematic Review of Clinical Outcomes, Treatment Interactions, and Emerging Technologies.” Journal of clinical medicine (2025). PMID: 39941652 ↗

    L2SR_OBSCited in: Quantitative Parameters, Equations & Curves
  80. [80]

    Heuts S, Kawczynski MJ, Leus A et al.. “The volume-outcome relationship for pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension.” The European respiratory journal (2025). PMID: 39572220 ↗

    L1SR_OBSCited in: Quantitative Parameters, Equations & Curves
  81. [81]

    Su J, Hilberg O, Howard L et al.. “A review of wave mechanics in the pulmonary artery with an emphasis on wave intensity analysis.” Acta physiologica (Oxford, England) (2016). PMID: 27636734 ↗

    L5REVIEW_NARRATIVECited in: Quantitative Parameters, Equations & Curves, Measurement & Assessment Methods, Clinical Correlation: From Derangement to Disease, Key Pearls, Common Misconceptions & Self-Test
  82. [82]

    Creager MA, Barnes GD, Giri J et al.. “2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.” Circulation (2026). PMID: 41712677 ↗

    L1GUIDELINECited in: Measurement & Assessment Methods
  83. [83]

    Gilbert RM, Gleghorn JP. “Connecting clinical, environmental, and genetic factors point to an essential role for vitamin A signaling in the pathogenesis of congenital diaphragmatic hernia.” American journal of physiology. Lung cellular and molecular physiology (2023). PMID: 36749917 ↗

    L5REVIEW_NARRATIVECited in: Measurement & Assessment Methods, Physiological Variation
  84. [84]

    Creager MA, Barnes GD, Giri J et al.. “2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.” Journal of the American College of Cardiology (2026). PMID: 41712898 ↗

    L1GUIDELINECited in: Measurement & Assessment Methods
  85. [85]

    Eini P, Serpoush H, Rezayee M et al.. “"Diagnostic Performance of Artificial Intelligence in Evaluating Tricuspid Regurgitation: A Systematic Review and Meta-Analysis".” Clinical cardiology (2026). PMID: 42244453 ↗

    L1SR_OBSCited in: Measurement & Assessment Methods, Clinical Correlation: From Derangement to Disease
  86. [86]

    Lundgren J, Rådegran G. “Pathophysiology and potential treatments of pulmonary hypertension due to systolic left heart failure.” Acta physiologica (Oxford, England) (2014). PMID: 24703457 ↗

    L5REVIEW_NARRATIVECited in: Measurement & Assessment Methods, Clinical Correlation: From Derangement to Disease, Key Pearls, Common Misconceptions & Self-Test
  87. [87]

    Sylvester JT, Shimoda LA, Aaronson PI et al.. “Hypoxic pulmonary vasoconstriction.” Physiological reviews (2012). PMID: 22298659 ↗

    L5REVIEW_NARRATIVECited in: Physiological Variation, Key Pearls, Common Misconceptions & Self-Test
  88. [88]

    Naeije R, Chesler N. “Pulmonary circulation at exercise.” Comprehensive Physiology (2012). PMID: 23105961 ↗

    L5REVIEW_NARRATIVECited in: Physiological Variation, Clinical Correlation: From Derangement to Disease
  89. [89]

    Belkin MN, Fudim M, Baratto C et al.. “Standardization of Baseline and Provocative Invasive Hemodynamic Protocols for the Evaluation of Heart Failure and Pulmonary Hypertension: A Scientific Statement From the American Heart Association.” Circulation. Heart failure (2026). PMID: 41493051 ↗

    L1GUIDELINECited in: Physiological Variation
  90. [90]

    Martin YN, Pabelick CM. “Sex differences in the pulmonary circulation: implications for pulmonary hypertension.” American journal of physiology. Heart and circulatory physiology (2014). PMID: 24610923 ↗

    L5REVIEW_NARRATIVECited in: Physiological Variation, Clinical Correlation: From Derangement to Disease, Key Pearls, Common Misconceptions & Self-Test
  91. [91]

    Hensley MK, Levine A, Gladwin MT et al.. “Emerging therapeutics in pulmonary hypertension.” American journal of physiology. Lung cellular and molecular physiology (2018). PMID: 29388467 ↗

    L5REVIEW_NARRATIVECited in: Physiological Variation, Clinical Correlation: From Derangement to Disease, Key Pearls, Common Misconceptions & Self-Test
  92. [92]

    Gomez-Arroyo J, Saleem SJ, Mizuno S et al.. “A brief overview of mouse models of pulmonary arterial hypertension: problems and prospects.” American journal of physiology. Lung cellular and molecular physiology (2012). PMID: 22307907 ↗

    L5REVIEW_NARRATIVECited in: Physiological Variation
  93. [93]

    Karim L, Kosmider B, Bahmed K. “Mitochondrial ribosomal stress in lung diseases.” American journal of physiology. Lung cellular and molecular physiology (2021). PMID: 34873929 ↗

    L5REVIEW_NARRATIVECited in: Physiological Variation, Clinical Correlation: From Derangement to Disease, Key Pearls, Common Misconceptions & Self-Test
  94. [94]

    Said SI. “Mediators and modulators of pulmonary arterial hypertension.” American journal of physiology. Lung cellular and molecular physiology (2006). PMID: 16698850 ↗

    L5REVIEW_NARRATIVECited in: Physiological Variation, Clinical Correlation: From Derangement to Disease
  95. [95]

    Frump AL, Bonnet S, de Jesus Perez VA et al.. “Emerging role of angiogenesis in adaptive and maladaptive right ventricular remodeling in pulmonary hypertension.” American journal of physiology. Lung cellular and molecular physiology (2017). PMID: 29097426 ↗

    L5REVIEW_NARRATIVECited in: Physiological Variation
  96. [96]

    R Murad M, Awashra A, S Elgendy M et al.. “Clinical, hemodynamic, and safety outcomes of sotatercept in pulmonary arterial hypertension: a meta-analysis of randomized trials with time-to-event data.” Therapeutic advances in respiratory disease (2026). PMID: 42312805 ↗

    L1SR_OBSCited in: Physiological Variation, Clinical Correlation: From Derangement to Disease, Key Pearls, Common Misconceptions & Self-Test
  97. [97]

    Cekirdekci EI, Onar LC. “Clinical and Hemodynamic Effects of Pulmonary Artery Denervation in Pulmonary Hypertension Despite Optimized Pharmacotherapy: An Updated Systematic Review and Meta-Analysis.” Journal of clinical medicine (2026). PMID: 41976921 ↗

    L1SR_OBSCited in: Physiological Variation
  98. [98]

    Heath-Freudenthal A, Estrada A, von Alvensleben I et al.. “Surviving birth at high altitude.” The Journal of physiology (2024). PMID: 38520695 ↗

    L5REVIEW_NARRATIVECited in: Physiological Variation, Clinical Correlation: From Derangement to Disease, Key Pearls, Common Misconceptions & Self-Test
  99. [99]

    Titz A, Schneider S, Mueller J et al.. “Symposium review: high altitude travel with pulmonary vascular disease.” The Journal of physiology (2024). PMID: 38780974 ↗

    L5REVIEW_NARRATIVECited in: Physiological Variation, Clinical Correlation: From Derangement to Disease
  100. [100]

    Lai YC, Wang L, Gladwin MT. “Insights into the pulmonary vascular complications of heart failure with preserved ejection fraction.” The Journal of physiology (2018). PMID: 30549058 ↗

    L5REVIEW_NARRATIVECited in: Physiological Variation
  101. [101]

    Ronen R, Zhou D, Bafna V et al.. “The genetic basis of chronic mountain sickness.” Physiology (Bethesda, Md.) (2014). PMID: 25362634 ↗

    L5REVIEW_NARRATIVECited in: Physiological Variation, Clinical Correlation: From Derangement to Disease, Key Pearls, Common Misconceptions & Self-Test
  102. [102]

    Kylhammar D, Rådegran G. “The principal pathways involved in the in vivo modulation of hypoxic pulmonary vasoconstriction, pulmonary arterial remodelling and pulmonary hypertension.” Acta physiologica (Oxford, England) (2016). PMID: 27381367 ↗

    L5REVIEW_NARRATIVECited in: Physiological Variation, Key Pearls, Common Misconceptions & Self-Test
  103. [103]

    Ambalavanan N, Deutsch G, Pryhuber G et al.. “The evolving pathophysiology of bronchopulmonary dysplasia.” Physiological reviews (2025). PMID: 40880213 ↗

    L5REVIEW_NARRATIVECited in: Clinical Correlation: From Derangement to Disease, Key Pearls, Common Misconceptions & Self-Test
  104. [104]

    Francis SH, Blount MA, Corbin JD. “Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions.” Physiological reviews (2011). PMID: 21527734 ↗

    L5REVIEW_NARRATIVECited in: Clinical Correlation: From Derangement to Disease
  105. [105]

    Navarro-Llinares L, García-León B, de la Bastida-Casero L et al.. “The Vascular-Immune Cells Crosstalk and Microenvironment in Pulmonary Hypertension.” Comprehensive Physiology (2026). PMID: 41687017 ↗

    L5REVIEW_NARRATIVECited in: Clinical Correlation: From Derangement to Disease
  106. [106]

    Hester J, Ventetuolo C, Lahm T. “Sex, Gender, and Sex Hormones in Pulmonary Hypertension and Right Ventricular Failure.” Comprehensive Physiology (2019). PMID: 31853950 ↗

    L5REVIEW_NARRATIVECited in: Clinical Correlation: From Derangement to Disease, Key Pearls, Common Misconceptions & Self-Test
  107. [107]

    Tajsic T, Morrell NW. “Smooth muscle cell hypertrophy, proliferation, migration and apoptosis in pulmonary hypertension.” Comprehensive Physiology (2011). PMID: 23737174 ↗

    L5REVIEW_NARRATIVECited in: Clinical Correlation: From Derangement to Disease, Key Pearls, Common Misconceptions & Self-Test
  108. [108]

    Kang Y, Wang S, Huang J et al.. “Right ventricular dysfunction and remodeling in diabetic cardiomyopathy.” American journal of physiology. Heart and circulatory physiology (2018). PMID: 30412438 ↗

    L5REVIEW_NARRATIVECited in: Clinical Correlation: From Derangement to Disease, Key Pearls, Common Misconceptions & Self-Test
  109. [109]

    Christou H, Khalil RA. “Mechanisms of pulmonary vascular dysfunction in pulmonary hypertension and implications for novel therapies.” American journal of physiology. Heart and circulatory physiology (2022). PMID: 35213243 ↗

    L5REVIEW_NARRATIVECited in: Clinical Correlation: From Derangement to Disease
  110. [110]

    Aradhyula V, Vyas R, Dube P et al.. “Novel insights into the pathobiology of pulmonary hypertension in heart failure with preserved ejection fraction.” American journal of physiology. Heart and circulatory physiology (2024). PMID: 38639739 ↗

    L5REVIEW_NARRATIVECited in: Clinical Correlation: From Derangement to Disease, Key Pearls, Common Misconceptions & Self-Test
  111. [111]

    Mathew R. “Pathogenesis of pulmonary hypertension: a case for caveolin-1 and cell membrane integrity.” American journal of physiology. Heart and circulatory physiology (2013). PMID: 24163076 ↗

    L5REVIEW_NARRATIVECited in: Clinical Correlation: From Derangement to Disease
  112. [112]

    Potoka KP, Gladwin MT. “Vasculopathy and pulmonary hypertension in sickle cell disease.” American journal of physiology. Lung cellular and molecular physiology (2014). PMID: 25398989 ↗

    L5REVIEW_NARRATIVECited in: Clinical Correlation: From Derangement to Disease
  113. [113]

    Breitling S, Ravindran K, Goldenberg NM et al.. “The pathophysiology of pulmonary hypertension in left heart disease.” American journal of physiology. Lung cellular and molecular physiology (2015). PMID: 26502478 ↗

    L5REVIEW_NARRATIVECited in: Clinical Correlation: From Derangement to Disease
  114. [114]

    Gibson W, Wunderlich NC, Alranini I et al.. “Predictors of Procedural and Clinical Outcomes Following Transcatheter Tricuspid Edge-to-Edge Repair: An Expert Overview.” JACC. Cardiovascular interventions (2026). PMID: 42191312 ↗

    L1SR_OBSCited in: Clinical Correlation: From Derangement to Disease, Key Pearls, Common Misconceptions & Self-Test
  115. [115]

    Li G, Du X, Luo W et al.. “Efficacy and safety of bosentan-related therapy in neonates with persistent pulmonary hypertension of the newborn: a systematic review and meta-analysis.” Frontiers in pediatrics (2026). PMID: 42317665 ↗

    L1SR_OBSCited in: Clinical Correlation: From Derangement to Disease
  116. [116]

    Nakahara S, Hirao Y, Fujiuchi B et al.. “Inhaled nitric oxide in fibrotic and advanced interstitial lung disease: A systematic review and meta-analysis of randomized controlled trials.” PloS one (2026). PMID: 42329957 ↗

    L1SR_MA_RCTCited in: Clinical Correlation: From Derangement to Disease
  117. [117]

    An JE, Cho J, Kim MJ et al.. “Indirect Treatment Comparison of Riociguat Replacement Therapy and Selexipag Add-on Therapy in Patients With Pulmonary Arterial Hypertension: Results From a Systematic Review.” Reviews in cardiovascular medicine (2026). PMID: 42238623 ↗

    L2SR_OBSCited in: Clinical Correlation: From Derangement to Disease
  118. [118]

    Guasti E, Tardini G, Buratti S et al.. “Alveolar Capillary Dysplasia With Misaligned Pulmonary Veins (ACDMPV): Description of Two Cases and Literature Review.” Pediatric pulmonology (2026). PMID: 42324883 ↗

    L4CASE_REPORTCited in: Clinical Correlation: From Derangement to Disease
  119. [119]

    Wszelaki P, Karczmarska A, Szymoniuk S et al.. “The Role of Platelets in Pulmonary Hypertension: From Activation to Pulmonary Vascular Remodeling-A Review Article.” Biomedicines (2026). PMID: 42351631 ↗

    L5REVIEW_NARRATIVECited in: Clinical Correlation: From Derangement to Disease
  120. [120]

    Mohammed A, Hussein S, Mahdi G et al.. “The Utility of Extracorporeal Membrane Oxygenation in the Setting of Chronic Thromboembolic Pulmonary Hypertension.” Medical sciences (Basel, Switzerland) (2026). PMID: 42346812 ↗

    L5REVIEW_NARRATIVECited in: Clinical Correlation: From Derangement to Disease
  121. [121]

    Willson C, Watanabe M, Tsuji-Hosokawa A et al.. “Pulmonary vascular dysfunction in metabolic syndrome.” The Journal of physiology (2018). PMID: 30125956 ↗

    L5REVIEW_NARRATIVECited in: Clinical Correlation: From Derangement to Disease, Key Pearls, Common Misconceptions & Self-Test
  122. [122]

    Goss K. “Long-term pulmonary vascular consequences of perinatal insults.” The Journal of physiology (2018). PMID: 30067297 ↗

    L5REVIEW_NARRATIVECited in: Clinical Correlation: From Derangement to Disease
  123. [123]

    Saco TV, Parthasarathy PT, Cho Y et al.. “Role of epigenetics in pulmonary hypertension.” American journal of physiology. Cell physiology (2014). PMID: 24717578 ↗

    L5REVIEW_NARRATIVECited in: Clinical Correlation: From Derangement to Disease, Key Pearls, Common Misconceptions & Self-Test
  124. [124]

    Rode B, Bailey MA, Marthan R et al.. “ORAI Channels as Potential Therapeutic Targets in Pulmonary Hypertension.” Physiology (Bethesda, Md.) (2018). PMID: 29897302 ↗

    L5REVIEW_NARRATIVECited in: Clinical Correlation: From Derangement to Disease, Key Pearls, Common Misconceptions & Self-Test

Revision History

All updates applied to this page

Loading revisions…